Predictors of androgen deprivation therapy efficacy combined with prostatic irradiation: The central role of tumor stage and radiation dose

International Journal of Radiation Oncology Biology Physics

Volumn 79, Issue 3, 2011, Pages 724-731

  Williams, Scott ^a   Buyyounouski, Mark ^b   Kestin, Larry ^c   Duchesne, Gillian ^a   Pickles, Tom ^d  

^a UNIVERSITY OF MELBOURNE   (Australia)

^b FOX CHASE CANCER CENTER   (United States)

^c WILLIAM BEAUMONT HOSPITAL   (United States)

^d BRITISH COLUMBIA CANCER AGENCY   (Canada)

Author keywords

Androgen deprivation; Outcomes; Prostate cancer; Radiotherapy

Indexed keywords

ANDROGEN DEPRIVATION; ANDROGEN DEPRIVATION THERAPY; BIOCHEMICAL FAILURE; CONFIDENCE INTERVAL; EXTERNAL BEAM RADIOTHERAPY; GLEASON SCORES; HIGHER T; INDIVIDUAL PREDICTION; INTERACTION ANALYSIS; LOCALIZED PROSTATE CANCER; OUTCOMES; POTENTIAL BENEFITS; PRE-TREATMENT; PREDICTIVE FACTORS; PROSPECTIVE EVALUATION; PROSTATE CANCER; PROSTATE CANCERS; PROSTATE SPECIFIC ANTIGEN; RADIATION DOSE;

DECISION MAKING; DISEASES; DOSIMETRY; PATIENT MONITORING; RADIATION EFFECTS; TUMORS;

RADIOTHERAPY;

PROSTATE SPECIFIC ANTIGEN;

ANDROGEN DEPRIVATION THERAPY; ARTICLE; CANCER STAGING; DRUG EFFICACY; EXTERNAL BEAM RADIOTHERAPY; HUMAN; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; PROSTATE CANCER; RADIATION DOSE; RISK REDUCTION; TREATMENT DURATION; TREATMENT FAILURE; TREATMENT PLANNING; TREATMENT RESPONSE;

AGED; AGED, 80 AND OVER; ANDROGEN ANTAGONISTS; CHEMOTHERAPY, ADJUVANT; CONFIDENCE INTERVALS; FOLLOW-UP STUDIES; HUMANS; MALE; MIDDLE AGED; NEOPLASM STAGING; PROSTATE; PROSTATE-SPECIFIC ANTIGEN; PROSTATIC NEOPLASMS; RADIOTHERAPY DOSAGE; TREATMENT OUTCOME;

EID: 79551481697     PISSN: 03603016     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ijrobp.2009.11.044     Document Type: Article

References (41)

1. M. Bolla, L. Collette, and L. Blank Long-term results with immediate androgen suppression and external irradiation in patients with locally advanced prostate cancer (an EORTC study): A phase III randomised trial Lancet 360 2002 103 106
2. G.E. Hanks, T.F. Pajak, and A. Porter Phase III trial of long-term adjuvant androgen deprivation after neoadjuvant hormonal cytoreduction and radiotherapy in locally advanced carcinoma of the prostate: The Radiation Therapy Oncology Group Protocol 92-02 J Clin Oncol 21 2003 3972 3978
3. M.V. Pilepich, R. Caplan, and R.W. Byhardt Phase III trial of androgen suppression using goserelin in unfavorable-prognosis carcinoma of the prostate treated with definitive radiotherapy: Report of Radiation Therapy Oncology Group Protocol 85-31 J Clin Oncol 15 1997 1013 1021
4. J.W. Denham, A. Steigler, and D.S. Lamb Short-term androgen deprivation and radiotherapy for locally advanced prostate cancer: Results from the Trans-Tasman Radiation Oncology Group 96.01 randomised controlled trial Lancet Oncol 6 2005 841 850
5. M.R. Cooperberg, G.D. Grossfeld, and D.P. Lubeck National practice patterns and time trends in androgen ablation for localized prostate cancer J Natl Cancer Inst 95 2003 981 989
6. M. Roach 3rd, J. Lu, and M.V. Pilepich Predicting long-term survival, and the need for hormonal therapy: A meta-analysis of RTOG prostate cancer trials Int J Radiat Oncol Biol Phys 47 2000 617 627
7. M. Beasley, S.G. Williams, and T. Pickles Expanded risk groups help determine which prostate radiotherapy sub-group may benefit from adjuvant androgen deprivation therapy Radiat Oncol 3 2008 8
8. D.A. Loblaw, D.S. Mendelson, and J.A. Talcott American Society of Clinical Oncology recommendations for the initial hormonal management of androgen-sensitive metastatic, recurrent, or progressive prostate cancer J Clin Oncol 22 2004 2927 2941
9. N.L. Keating, A.J. OMalley, and M.R. Smith Diabetes and cardiovascular disease during androgen deprivation therapy for prostate cancer J Clin Oncol 24 2006 4448 4456
10. M.R. Smith, W.C. Lee, and J. Brandman Gonadotropin-releasing hormone agonists and fracture risk: A claims-based cohort study of men with nonmetastatic prostate cancer J Clin Oncol 23 2005 7897 7903
11. H.J. Green, K.I. Pakenham, and B.C. Headley Quality of life compared during pharmacological treatments and clinical monitoring for non-localized prostate cancer: A randomized controlled trial BJU Int 93 2004 975 979
12. R.R. Bahnson, G.E. Hanks, and R.P. Huben NCCN practice guidelines for prostate cancer Oncology (Williston Park) 14 2000 111 119
13. T. Pickles, C. Kim-Sing, and W.J. Morris Evaluation of the Houston biochemical relapse definition in men treated with prolonged neoadjuvant and adjuvant androgen ablation and assessment of follow-up lead-time bias Int J Radiat Oncol Biol Phys 57 2003 11 18
14. M.K. Buyyounouski, A.L. Hanlon, and D.F. Eisenberg Defining biochemical failure after radiotherapy with and without androgen deprivation for prostate cancer Int J Radiat Oncol Biol Phys 63 2005 1455 1462
15. L.L. Kestin, F.A. Vicini, and A.A. Martinez Practical application of biochemical failure definitions: What to do and when to do it Int J Radiat Oncol Biol Phys 53 2002 304 315
16. S.G. Williams, M.K. Buyyounouski, and T. Pickles Percentage of biopsy cores positive for malignancy and biochemical failure following prostate cancer radiotherapy in 3,264 men: Statistical significance without predictive performance Int J Radiat Oncol Biol Phys 70 2008 1169 1175
17. M. Roach 3rd, G. Hanks, and H. Thames Jr. Defining biochemical failure following radiotherapy with or without hormonal therapy in men with clinically localized prostate cancer: Recommendations of the RTOG-ASTRO Phoenix consensus conference Int J Radiat Oncol Biol Phys 65 2006 965 974
18. F.E. Harrell Jr., K.L. Lee, and D.B. Mark Multivariable prognostic models: Issues in developing models, evaluating assumptions and adequacy, and measuring and reducing errors Stat Med 15 1996 361 387
19. S.F. Assmann, S.J. Pocock, and L.E. Enos Subgroup analysis and other (mis)uses of baseline data in clinical trials Lancet 355 2000 1064 1069
20. M. Bolla, D. Gonzalez, and P. Warde Improved survival in patients with locally advanced prostate cancer treated with radiotherapy and goserelin N Engl J Med 337 1997 295 300
21. M.V. Pilepich, K. Winter, and M.J. John Phase III radiation therapy oncology group (RTOG) trial 86-10 of androgen deprivation adjuvant to definitive radiotherapy in locally advanced carcinoma of the prostate Int J Radiat Oncol Biol Phys 50 2001 1243 1252
22. S. Park, M.V. Meng, and E.P. Elkin Androgen deprivation use with external beam radiation for prostate cancer: Results from CaPSURE J Urol 174 2005 1802 1807
23. V.B. Shahinian, Y.F. Kuo, and J.L. Freeman Increasing use of gonadotropin-releasing hormone agonists for the treatment of localized prostate carcinoma Cancer 103 2005 1615 1624
24. C.J. Weight, E.A. Klein, and J.S. Jones Androgen deprivation falls as orchiectomy rates rise after changes in reimbursement in the U.S. Medicare population Cancer 112 2008 2195 2201
25. J. Mohler, R.J. Babaian, and R.R. Bahnson Prostate cancer. Clinical practice guidelines in oncology J Natl Compr Cancer Network 5 2007 650 683
26. D.A. Kuban, S.L. Tucker, and L. Dong Long-term results of the M.D. Anderson randomized dose-escalation trial for prostate cancer Int J Radiat Oncol Biol Phys 70 2008 67 74
27. A.L. Zietman, M.L. DeSilvio, and J.D. Slater Comparison of conventional-dose vs high-dose conformal radiation therapy in clinically localized adenocarcinoma of the prostate: a randomized controlled trial JAMA 294 2005 1233 1239
28. G.L. Lu-Yao, P.C. Albertsen, and D.F. Moore Survival following primary androgen deprivation therapy among men with localized prostate cancer JAMA 300 2008 173 181
29. A.L. Zietman Correction: Inaccurate analysis and results in a study of radiation therapy in adenocarcinoma of the prostate JAMA 299 2008 898 899
30. D.P. Dearnaley, M.R. Sydes, and J.D. Graham Escalated-dose versus standard-dose conformal radiotherapy in prostate cancer: First results from the MRC RT01 randomised controlled trial Lancet Oncol 8 2007 475 487
31. S.T.H. Peeters, W.D. Heemsbergen, P.C.M. Koper, W.L.J. van Putten, A. Slot, M.F.H. Dielwart, J.M.G. Bonfrer, L. IncrocCi, and J.V. Lebesque Dose-response in radiotherapy for localized prostate cancer: Results of the Dutch Multicenter Randomised Phase III Trial comparing 68 Gy of radiotherapy with 78 Gy J Clin Oncol 24 2006 1990 1996
32. A.V. DAmico, J. Manola, and M. Loffredo 6-month androgen suppression plus radiation therapy vs radiation therapy alone for patients with clinically localized prostate cancer: A randomized controlled trial JAMA 292 2004 821 827
33. A.V. DAmico, J.W. Denham, and J. Crook Influence of androgen suppression therapy for prostate cancer on the frequency and timing of fatal myocardial infarctions J Clin Oncol 25 2007 2420 2425
34. T. Pickles, A. Agranovich, and E. Berthelet Testosterone recovery following prolonged adjuvant androgen ablation for prostate carcinoma Cancer 94 2002 362 367
35. N.A. Spry, L. Kristjanson, and B. Hooton Adverse effects to quality of life arising from treatment can recover with intermittent androgen suppression in men with prostate cancer Eur J Cancer 42 2006 1083 1092
36. H.K. Tsai, A.V. DAmico, and N. Sadetsky Androgen deprivation therapy for localized prostate cancer and the risk of cardiovascular mortality J Natl Cancer Inst 99 2007 1516 1524
37. A. Nanda, M.H. Chen, and M.H. Braccioforte Hormonal therapy use for prostate cancer and mortality in men with coronary artery disease-induced congestive heart failure or myocardial infarction JAMA 302 2009 866 873
38. E.D. Crawford, C.L. Bennett, and N.N. Stone Comparison of perspectives on prostate cancer: analyses of survey data Urology 50 1997 366 372
39. J.J. van Tol-Geerdink, P.F. Stalmeier, and E.N. van Lin Do patients with localized prostate cancer treatment really want more aggressive treatment? J Clin Oncol 24 2006 4581 4586
40. K. Antman, D. Amato, and W. Wood Selection bias in clinical trials J Clin Oncol 3 1985 1142 1147
41. M. Bolla, T.M. de Reijke, and G. Van Tienhoven Duration of androgen suppression in the treatment of prostate cancer N Engl J Med 360 2009 2516 2527